Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353
Amesika N. Nyaku*, Lu Zheng, Roy M. Gulick, Maxine Olefsky, Baiba Berzins, Carole L. Wallis, Catherine Godfrey, Paul E. Sax, Edward P. Acosta, David W. Haas, Kimberly Y. Smith, Beverly E. Sha, Cornelius N. Van Dam, Babafemi O. Taiwo, Elizabeth Hawkins, Johnstone Kumwenda, Angel Hernandez, Belinda Ha, Bernadette Jarocki, Gerald TeghaTanisha Sullivan
Dive into the research topics of 'Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353'. Together they form a unique fingerprint.